Austrália - inglês - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - hepatitis a virus antigen, quantity: 720 elisa unit - injection, suspension - excipient ingredients: aluminium hydroxide hydrate; aluminium; polysorbate 20; dibasic sodium phosphate heptahydrate; monobasic potassium phosphate; sodium chloride; potassium chloride; water for injections; acetic acid; leucine; phenylalanine; methionine; lysine hydrochloride; isoleucine; valine; histidine; threonine; tryptophan; alanine; arginine; proline; tyrosine; serine; sodium acetate; dibasic potassium phosphate; magnesium chloride hexahydrate; glycine - havrix is indicated for active immunisation against hepatitis a virus (hav) infection in susceptible subjects at risk of exposure to hav. havrix junior is indicated in subjects aged 2 to 15 years and havrix 1440 is indicated in subjects aged 16 years and older. in areas of low prevalence of hepatitis a, immunisation with havrix is particularly recommended in the following subjects: travellers : persons travelling to areas of intermediate or high endemicity for hepatitis a. these areas include africa, asia, india, the pacific islands, the mediterranean basin, the middle east, central and south america. armed forces : armed forces personnel who travel to higher endemicity areas or to areas where hygiene is poor, have an increased risk of hav infection. persons for whom hepatitis a is an occupational hazard or for whom there is an increased risk of transmission. these include: employees in day-care centres particularly in situations where children have not been toilet trained; teachers and other close contacts o

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - hepatitis a virus antigen, quantity: 1440 elisa unit - injection, suspension - excipient ingredients: polysorbate 20; dibasic sodium phosphate heptahydrate; monobasic potassium phosphate; sodium chloride; potassium chloride; water for injections; aluminium hydroxide hydrate; acetic acid; leucine; phenylalanine; methionine; lysine hydrochloride; isoleucine; valine; histidine; threonine; tryptophan; alanine; arginine; proline; tyrosine; serine; sodium acetate; dibasic potassium phosphate; magnesium chloride hexahydrate; glycine - havrix is indicated for active immunisation against hepatitis a virus (hav) infection in susceptible subjects at risk of exposure to hav. havrix junior is indicated in subjects aged 2 to 15 years and havrix 1440 is indicated in subjects aged 16 years and older. in areas of low prevalence of hepatitis a, immunisation with havrix is particularly recommended in the following subjects: travellers : persons travelling to areas of intermediate or high endemicity for hepatitis a. these areas include africa, asia, india, the pacific islands, the mediterranean basin, the middle east, central and south america. armed forces : armed forces personnel who travel to higher endemicity areas or to areas where hygiene is poor, have an increased risk of hav infection. persons for whom hepatitis a is an occupational hazard or for whom there is an increased risk of transmission. these include: employees in day-care centres particularly in situations where children have not been toilet trained; teachers and other close contacts o

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - bortezomib, quantity: 3.5 mg - injection, powder for - excipient ingredients: mannitol; nitrogen - bortezomib, in combination with melphalan and prednisone is indicated for the treatment of patients with previously untreated multiple myeloma who are not candidates for high dose chemotherapy.,bortezomib, as part of combination therapy, is indicated for induction therapy prior to high dose chemotherapy with autologous stem cell rescue for patients under 65 years of age with previously untreated multiple myeloma.,bortezomib is also indicated for the treatment of multiple myeloma patients who have received at least one prior therapy, and who have progressive disease.,bortezomib in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - bortezomib, quantity: 2.5 mg - injection, powder for - excipient ingredients: mannitol; nitrogen - dbl bortezomib powder for injection, in combination with melphalan and prednisone is indicated for the treatment of patients with previously untreated multiple myeloma who are not candidates for high dose chemotherapy. dbl bortezomib powder for injection, as part of combination therapy, is indicated for induction therapy prior to high dose chemotherapy with autologous stem cell rescue for patients under 65 years of age with previously untreated multiple myeloma. dbl bortezomib powder for injection is also indicated for the treatment of multiple myeloma patients who have received at least one prior therapy, and who have progressive disease. dbl bortezomib powder for injection in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - bortezomib, quantity: 3.5 mg - injection, powder for - excipient ingredients: mannitol; nitrogen - dbl bortezomib powder for injection, in combination with melphalan and prednisone is indicated for the treatment of patients with previously untreated multiple myeloma who are not candidates for high dose chemotherapy. dbl bortezomib powder for injection, as part of combination therapy, is indicated for induction therapy prior to high dose chemotherapy with autologous stem cell rescue for patients under 65 years of age with previously untreated multiple myeloma. dbl bortezomib powder for injection is also indicated for the treatment of multiple myeloma patients who have received at least one prior therapy, and who have progressive disease. dbl bortezomib powder for injection in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - bortezomib, quantity: 3 mg - injection, powder for - excipient ingredients: mannitol; nitrogen - dbl bortezomib powder for injection, in combination with melphalan and prednisone is indicated for the treatment of patients with previously untreated multiple myeloma who are not candidates for high dose chemotherapy. dbl bortezomib powder for injection, as part of combination therapy, is indicated for induction therapy prior to high dose chemotherapy with autologous stem cell rescue for patients under 65 years of age with previously untreated multiple myeloma. dbl bortezomib powder for injection is also indicated for the treatment of multiple myeloma patients who have received at least one prior therapy, and who have progressive disease. dbl bortezomib powder for injection in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - bortezomib - injection, powder for - excipient ingredients: mannitol; nitrogen - bortezomib powder for injection, in combination with melphalan and prednisone is indicated for the treatment of patients with previously untreated multiple myeloma who are not candidates for high dose chemotherapy. bortezomib powder for injection, as part of combination therapy, is indicated for induction therapy prior to high dose chemotherapy with autologous stem cell rescue for patients under 65 years of age with previously untreated multiple myeloma. bortezomib powder for injection is also indicated for the treatment of multiple myeloma patients who have received at least one prior therapy, and who have progressive disease. bortezomib powder for injection in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma.

Austrália - inglês - APVMA (Australian Pesticides and Veterinary Medicines Authority)

amgrow pty ltd - boron as disodium octoborate tetrahydrate & orthoboric a; orthoboric acid; benzalkonium chloride; mono ethylene glycol - paint - boron as disodium octoborate tetrahydrate & orthoboric a mineral-boron active 108.0 g/l; orthoboric acid mineral-boron active 200.0 g/l; benzalkonium chloride ammonium-quaternary active 20.0 g/l; mono ethylene glycol ungrouped other 200.0 g/l - mixed function pesticide - brick work | concrete | masonary | timber | brick structures | brick wall | bricks | painted concrete | path | paving | unpainte - algae | borer | decay prevention or preservation | fungus | mould | termite - mastotermes spp. | fungal leaf spots | fungi | fungus diseases | giant northern termite | gives longer life | leaf spot diseases | leaf spots | mastotermes darwiniensis

Austrália - inglês - APVMA (Australian Pesticides and Veterinary Medicines Authority)

preschem pty. ltd. - boron present as disodium octaborate tetrahydrate; benzalkonium chloride; mono ethylene glycol - gel - boron present as disodium octaborate tetrahydrate mineral-boron active 111.0 g/l; benzalkonium chloride ammonium-quaternary active 13.2 g/l; mono ethylene glycol ungrouped other 739.0 g/l - wood preservative - brickwork and/or path | concrete | timber | painted concrete | unpainted concrete | wood - algae | borer | fungal decay | mould | termite - mastotermes spp. | decay fungi | giant northern termite | mastotermes darwiniensis

Austrália - inglês - APVMA (Australian Pesticides and Veterinary Medicines Authority)

preschem pty. ltd. - boron present as disodium octaborate tetrahydrate; benzalkonium chloride; mono ethylene glycol - lotion - boron present as disodium octaborate tetrahydrate mineral-boron active 52.0 g/l; benzalkonium chloride ammonium-quaternary active 12.0 g/l; mono ethylene glycol ungrouped other 878.0 g/l - mixed function pesticide - brick work | concrete | masonry | timber | brick structures | brick wall | bricks | painted concrete | path | paving | unpainted - algae | decay prevention or preservation | fungus | insect pest of timber | mould | termite | woodborer | anobiid | borers | drywood termite | fungal leaf spots | fungi | fungus diseases | gives longer life | leaf spot diseases | leaf spots | lyctid | lyctids | quarantine timber insects | subterranean termite | termite | timber destroying insects